Based on a combination of claims data and laboratory data obtained throughout Japan, we identified five AKI-related factors: prior treatment with ACE inhibitors/ARBs or carbapenem, concomitant administration of catecholamines or immunosuppressants, and ≥ 3.52 mg/kg/day of L-AMB dosing. The gene discussed is ACE; the disease is acute kidney injury.